[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-open-angle-glaucoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-open-angle-glaucoma":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,42,66,92,129,151,176,196,227,249,274,293,321,348,367,388,411,433,454,483,508,529,557,579,601],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100579318","phase-3-a-study-to-assess-adverse-events-and-effectiveness-of-gel-stent-xen63-implantation-using-ab-interno-and-ab-externo-approaches-in-adult-participants-with-glaucoma-100579318",false,"NCT06822738","A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma","A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Subjects With Glaucoma","Inclusion Criteria:\n\n* Diagnosis of glaucoma in the study eye (SE) (meeting criterion a or b)\n\n  1. That meets the following refractory glaucoma criteria of eyes diagnosed with glaucoma uncontrolled by maximal medical therapy (four or more classes of intraocular pressure (IOP)-lowering medications, or fewer in cases where it has been documented that certain medication classes cannot be tolerated or are contraindicated), and failed one or more incisional intraocular glaucoma surgeries (e.g., glaucoma filtering surgery, tube shunt)\n  2. Uncontrolled by medical therapy (to meet out-of-US \\[OUS\\] requirements) with participants who only have glaucoma uncontrolled by medical therapy (non-refractory glaucoma), a maximum of 10 participants who meet only criterion b (and not a) will be enrolled in each cohort.\n\n     Exclusion Criteria:\n* History of angle-closure glaucoma where the angle has not been surgically opened in the SE.\n* History of secondary open-angle glaucoma (e.g., neovascular, pigmentary, pseudoexfoliative, uveitic, angle recession\u002Ftraumatic glaucoma, etc.) in the SE.\n* Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis) in the SE.","ALL","45 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab interno (inside the eye) and ab externo (outside the eye) approach. Adverse events and intraocular pressure will be assessed.\n\nXEN63 is an investigational device for the treatment of intraocular pressure (IOP) in patients with glaucoma when both medical and conventional surgical treatments have failed (for US approval) and when medical treatments have failed (for outside US \\[OUS\\] approval). Participants will be placed in one of two groups called study arms. One group will receive the XEN63 gel stent ab interno (inside the eye) and the other group will receive the XEN63 gel stent ab externo (outside the eye). Approximately 130 participants aged 45 years or older with glaucoma will be enrolled in this study at approximately 32 sites in the United States.\n\nParticipants will receive XEN63 implanted using either the ab interno approach or the ab externo approach on Day 1 and will be followed for 12 months.\n\nParticipants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.",[27],"Primary Open Angle Glaucoma",[27,29],"AGN-9003","RECRUITING","2026-06-24",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":34},"2025-02-11",{"date":38,"type":21},"2028-11",{"name":40,"class":41},"AbbVie","INDUSTRY",{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100404988","hydrus-microstent-new-enrollment-post-approval-study-100404988","NCT04553523","Hydrus® Microstent New Enrollment Post-Approval Study","The Hydrus® Microstent New Enrollment Post-Approval Study: A Prospective, Non-Randomized, Multicenter, Single Arm, Clinical Trial","CONFIRM","Inclusion Criteria:\n\n* An operable, age-related cataract with best corrected visual acuity (BCVA) of 20\u002F40 or worse;\n* Diagnosis of primary open angle glaucoma treated with no more than 4 topical hypotensive medications;\n* Optic nerve appearance characteristic of glaucoma;\n* Medicated IOP less than or equal to 31 millimeters mercury (mmHg); Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Closed angle forms of glaucoma;\n* Congenital or developmental glaucoma;\n* Secondary glaucoma;\n* Use of more than 4 ocular hypotensive medications;\n* Previous argon laser trabeculoplasty, trabeculectomy, tube shunts, or any other prior filtration or cilioablative surgery;\n* Prior surgery with implanted device or other surgery involving the trabecular meshwork or Schlemm's canal;\n* Other protocol-defined exclusion criteria may apply.",{"count":51,"type":21},545,[53],"NA","The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.",[27],"2026-06-08",{"date":58,"type":34},"2026-06-10",{"date":60,"type":34},"2020-08-25",{"date":62,"type":21},"2028-06",{"name":64,"class":41},"Alcon Research",22,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100611054","preserflo-microshunt-xi-observational-pmcf-study-with-no-control-group-100611054","NCT07235592","PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group","Post Market Clinical Follow-Up Study to Demonstrate the Safety and Performance of the PRESERFLO™ MicroShunt XI in Patients With Primary Open Angle Glaucoma","Inclusion Criteria:\n\n1. Male or female, age 18 to 85 years, inclusive\n2. Patient diagnosed with primary open glaucoma where the IOP is not adequately controlled on maximum tolerated medical therapy and has intraocular pressure ≥18 mmHg and ≤35 mmHg while on glaucoma medications\n3. Patient willing to comply with study requirements\n4. Patient who has signed an approved informed consent form\n\nExclusion Criteria:\n\n1. Angle closure glaucoma\n2. Presence of conjunctival scarring, previous incisional ophthalmic surgery involving the conjunctiva or conjunctival pathologies (e.g., thin conjunctiva, pterygium)\n3. Active iris neovascularization\n4. Active inflammation (e.g., blepharitis, conjunctivitis, scleritis, keratitis, uveitis)\n5. Vitreous in the anterior chamber\n6. Presence of an anterior chamber intraocular lens (ACIOL)\n7. Intraocular silicone oil\n8. Need for glaucoma surgery combined with other ocular procedures (e.g., cataract surgery with IOL implantation) or anticipated need for additional ocular surgery during the investigational period\n9. Central corneal thickness that is less than 450 microns or greater than 620 microns\n10. Previous cilioablative procedure\n11. Neovascular glaucoma\n12. Uveitic Glaucoma\n13. Pseudoexfoliative or pigmentary glaucoma\n14. Chronic inflammation\n15. Previous incisional ophthalmic surgery within 6 months prior to study\n16. Enrolled in this or another study (only one eye can participate in this study) or completed their participation in another study within 30 calendar days of the screening exam\n17. Ocular pathology or medical condition for which, in the investigator's judgment, the following factors would either place the patient at increased risk of complications or contraindicate device implantation or interfere with compliance to elements of the Protocol","18 Years","85 Years",{"count":76,"type":21},112,"OBSERVATIONAL","The purpose of this study is to collect safety and performance data on the PRESERFLO™ MicroShunt XI in patients diagnosed with primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥18 mmHg and ≤35 mmHg and\u002For where glaucoma progression warrants surgery.",[27],[81],"POAG","2026-05-28",{"date":84,"type":34},"2026-05-29",{"date":86,"type":34},"2026-03-19",{"date":88,"type":21},"2027-09",{"name":90,"class":41},"Santen SAS",11,{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":105,"conditions":106,"keywords":111,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":128},"100640261","phase-1-topical-insulin-for-glaucoma-ting2-100640261","NCT07619482","Topical Insulin for Glaucoma (TING2)","A Phase 1\u002F2 Dose Escalation Followed by a Masked, Randomized, Placebo-Controlled Study to Evaluate Topical Insulin for Neuroprotection in Open Angle Glaucoma","Limited Inclusion Criteria - All Groups:\n\n* Provide written informed consent approved by the appropriate ethics committee\n* Age 18 years or older\n* Understand study procedures and have the ability and willingness to abide by all procedures during the study\n* Capable of providing informed consent\n* Diagnosis of glaucoma\n* Only one eye per patient will be selected as the study eye; if both eyes meet inclusion criteria, the eye with worse visual acuity and\u002For visual field will be selected\n\nLimited Exclusion Criteria - All Groups:\n\n* Pregnant or breastfeeding\n* Presence of any ocular pathology other than glaucoma that contributes to severe vision loss (retinopathy, maculopathy, severe uveitis, keratopathy, etc.)\n* Diagnosis of glucose intolerance, type 1 or type 2 diabetes mellitus\n* Inability to perform reliable visual field testing\n* Unable to provide informed consent\n* Unable to complete the tests and follow-ups required by the study","90 Years",{"count":101,"type":21},90,[103,104],"PHASE1","PHASE2","This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1\u002F2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.",[107,27,108,109,110],"Open Angle Glaucoma","Low Tension Glaucoma","Pigmentary Glaucoma","Pseudoexfoliation Glaucoma",[112,113,114,115,116],"glaucoma","neuroprotection","topical insulin","retinal ganglion cell","EYED-002","NOT_YET_RECRUITING","2026-05-26",{"date":120,"type":34},"2026-06-02",{"date":122,"type":21},"2026-06",{"date":124,"type":21},"2029-10",{"name":126,"class":127},"Stanford University","OTHER",1,{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100638331","phase-3-efficacy-and-safety-of-dnn3119026-for-ocular-hypertension-or-primary-open-angle-glaucoma-100638331","NCT07617532","Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma","A Randomized Clinical Trial to Evaluate the Safety and Efficacy of DNN.31.19.026 for the Treatment of Ocular Hypertension or Primary Open-Angle Glaucoma","RENOIR","Inclusion Criteria:\n\n* Participants of either sex, aged ≥18 years;\n* Participants diagnosed with ocular hypertension or primary open-angle glaucoma according to the Clinical Protocol and Therapeutic Guidelines for Glaucoma;\n* Participants requiring ocular hypotensive treatment in one or both eyes, for whom the use of combination topical ocular hypotensive medications is appropriate for intraocular pressure (IOP) reduction.\n\nExclusion Criteria:\n\n* Participants diagnosed with primary open-angle glaucoma with no prior treatment history for the disease;\n* Participants with a cup-to-disc ratio \\>0.8 (horizontal or vertical);\n* Participants with any other clinically significant ocular disease that, in the investigator's opinion, may interfere with the evaluation of study efficacy and safety variables;\n* Participants with ocular infection or inflammation within 3 months prior to the screening\u002Frun-in visit;\n* Participants with a history of trabeculoplasty (within the last 6 months) or surgical procedures for IOP reduction;\n* Participants with a history of ocular surgery within 6 months prior to the screening\u002Frun-in visit;\n* Participants with any corneal abnormality that may affect IOP measurement;\n* Participants with respiratory or pulmonary disorders, such as asthma or chronic obstructive pulmonary disease (COPD);\n* Participants with the following cardiac conditions: sinus bradycardia, sinoatrial block, second- or third-degree atrioventricular block, overt heart failure, or cardiogenic shock;\n* Participants with uncontrolled systemic diseases, such as diabetes, hypertension, chronic hepatic or renal disorders, or any other medical condition that, in the investigator's opinion, may interfere with the investigational product or comparator.",{"count":138,"type":21},336,[24],"This study aims to evaluate the safety and efficacy of DNN.31.19.026 compared with Cosopt® for the treatment of ocular hypertension or primary open-angle glaucoma.",[142,27],"Ocular Hypertension","2026-05-25",{"date":145,"type":34},"2026-06-01",{"date":122,"type":21},{"date":148,"type":21},"2028-03",{"name":150,"class":41},"Ache Laboratorios Farmaceuticos S.A.",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":157,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":128},"100638743","additive-efficacy-of-physical-activity-program-in-hypthyroidism-elder-females-with-glaucoma-and-fatty-liver-issues-100638743","NCT07599241","Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues","Inclusion Criteria:\n\n* subclinical hypothrodism (significant form)\n* primary opened angle gaulcoma in both eyes with ocular hypertension in both eyes )(high-tension typed glaucoma)\n* fatty liver (non alcholic type)\n* elder females\n\nExclusion Criteria:\n\n* respiratory issues\n* cardiac issues\n* renal issues","FEMALE","65 Years","75 Years",{"count":161,"type":21},40,[53],"additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated",[165,166,27],"Subclinical hypothyroïdism","Non-Alcoholic Fatty Liver Disease","2026-05-14",{"date":169,"type":34},"2026-05-20",{"date":171,"type":34},"2026-03-15",{"date":173,"type":21},"2026-12-15",{"name":175,"class":127},"Cairo University",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":128},"100622997","dslt-for-reducing-medication-in-glaucoma-100622997","NCT07390890","DSLT for Reducing Medication in Glaucoma","Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma","Inclusion Criteria:\n\n* Adult patients scheduled to undergo DSLT treatment in one or both eyes.\n\n  * Diagnosis of ocular hypertension or primary open angle glaucoma (POAG).\n* Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg.\n\nExclusion Criteria:\n\n* Previous glaucoma surgeries\u002Finterventions:\n\n  * Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).\n* Patients who have undergone cataract surgery within the prior 2 years.\n* Secondary glaucoma:\n\n  * Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.\n* Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.",{"count":184,"type":21},60,"This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma.\n\nThe study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT.\n\nParticipants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.",[27,142],"2026-04-17",{"date":189,"type":34},"2026-04-20",{"date":191,"type":34},"2026-02-10",{"date":193,"type":21},"2027-01-26",{"name":195,"class":127},"The Eye Institute of West Florida",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":204,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":213,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":225,"locationsCount":128},"100568571","transcorneal-electrical-stimulation-for-the-treatment-of-visual-field-defects-in-patients-with-open-angle-glaucoma-100568571","NCT06682962","Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma","Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma - a Monocentric, Randomized, Double-Masked, Sham-Controlled Pilot Study","TES-GPS","Inclusion Criteria:\n\n1. Willingness to participate in the study, the subjects signed and dated informed consent must be submitted before the start of the screening\n2. Age ≥ 40 years\n3. Primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or normal tension glaucoma (according to the EGS criteria) in the study eye\n4. Current progression in perimetry of at least 1.5 dB per year in the study eye and mean defect (MD) in the study eye between ≥ 6 and ≤ 12 dB (Octopus visual field) or ≤ -6 and ≥ -12 dB (Humphrey visual field) in the screening examination as the mean value of the two visual field examinations carried out as part of the screening (permitted deviation maximum 2 dB)\n5. Visual acuity ≥ 0.2 decimal in the study eye (corresponds to a visual acuity of 0.7 logMAR)\n6. The patient must master home stimulation after extensive training.\n7. Ability of subject to understand the scope, significance and individual consequences of participation in the study\n8. Ability of subject to give consent\n9. If both eyes meet the inclusion\u002Fexclusion criteria, the eye with the higher MD is selected as the study eye. If the MD is the same in both eyes, the eye with the worse visual acuity will be selected as the study eye. If there is no difference between the eyes, the right eye will be selected as the study eye\n10. Negative serum or urine pregnancy test at screening in women of childbearing potential. Participants are considered to be of nonchildbearing potential if they are postmenopausal and have not menstruated for at least 12 months prior to screening or if they are surgically sterile\n11. Women of childbearing potential must agree to be abstinent or to use highly effective methods of contraception that result in a failure rate of less than 1% per year. This applies consistently throughout the duration of the treatment once you have given your consent to participate in the study.\n\nExclusion Criteria:\n\n1. Neovascularisations of any origin in the study eye\n2. Condition after arterial or venous occlusions in the study eye\n3. Condition after intraocular surgery in the last 3 months before the screening examination in the study eye\n4. Acute (intra)ocular inflammation in any eye\n5. Non-proliferative or proliferative diabetic retinopathy in the study eye\n6. Condition after retinal detachment in the study eye\n7. Dry age-related macular degeneration affecting the visual field in the study eye\n8. Exsudative age-related macular degeneration in the study eye\n9. Macular edema of any origin in the study eye\n10. Other relevant retinal diseases in the study eye\n11. Any form of corneal degeneration that limits vision in the study eye\n12. Any disease other than glaucoma affecting the central 30° visual field in the study eye\n13. No cataract surgery or other eye surgery may be planned for the patient in the study eye during the duration of the study (except laser trabeculoplasty)\n14. Patients with active implants\n15. General illnesses that are difficult to control\u002Fadjust and which, in the opinion of the investigator, could jeopardize regular study routines\n16. Poor general condition according to the investigators assessment\n17. Mental illness or dementia, that, in the opinion of the investigator, reduces the understanding of the study procedures and use of the Okustim 2 System\n18. Simultaneous participation in another interventional study or past interventions whose effect may still be ongoing (30 days)\n19. Breastfeeding women\n20. Patients unable to consent\n21. Previous enrolment in the TES-GPS study\n22. Contraindications to the use of OkuStim 2 such as allergies\u002Fhypersensitivity to silver","40 Years",{"count":206,"type":21},50,[53],"Glaucoma is a progressive optic neuropathy with retinal ganglion cell loss which leads to visual field loss. Open-angle glaucoma is the most common form of glaucoma.\n\nThe aim of this pilot study is to evaluate the safety and effectiveness of the treatment of visual field defects using transcorneal electrical stimulation (TES) with the OkuStim 2 System in patients with primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or normal tension glaucoma.",[210,27,110,211,212],"Glaucoma","Pigment Dispersion Glaucoma","Normal Tension Glaucoma",[214,215,81,216,217,210,218],"TES","TcES","OkuStim","Okuvision","Electrical Stimulation","2026-03-10",{"date":221,"type":34},"2026-03-12",{"date":223,"type":34},"2025-04-02",{"date":62,"type":21},{"name":226,"class":41},"Okuvision GmbH",{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":128},"100627313","glaucoma-respsosne-to-lifestyle-corrections-in-sleep-apnea-100627313","NCT07447011","Glaucoma Respsosne to Lifestyle Corrections in Sleep Apnea","Inclusion Criteria:\n\n* Obstructive sleep apnea patients\n* obese patients\n* glaucoma (open angle form with ocular hyoertension)\n\nExclusion Criteria:\n\ncardiac patients renal patients hepatic patients","30 Years","50 Years",{"count":161,"type":21},[53],"glaucoma is prevalent among obstructive sleep apnea (OSA). contnous passive airway pressure is main treatment of OSA. lifestyle corrections also recommended",[27,239,240],"Obstructive Sleep Apnea","Obesity","2026-02-26",{"date":243,"type":34},"2026-03-03",{"date":245,"type":34},"2026-02-04",{"date":247,"type":21},"2026-07-20",{"name":175,"class":127},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":17,"minAge":204,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":273},"100620517","clinical-study-evaluating-the-safety-and-performance-of-the-mist-device-for-intraocular-pressure-reduction-in-patients-with-primary-open-angle-glaucoma-100620517","NCT07358650","Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma","A Multicenter, First-in-Human Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma","Inclusion Criteria:\n\n* Adults ≥ 40 years with uncontrolled mild to moderate POAG.\n* IOP ≥ 18 mmHg on ≥1 topical IOP-lowering medications.\n* Open angle on gonioscopy\n* Clear cornea and healthy ocular surface\n* Capable of giving informed consent, willingness to participate in the trial, and adhering to follow-up\n* Glaucomatous visual field loss in one or both eyes at presentation on any of these criteria:\n\n  * Reproducible and reliable visual field defects on 2 consecutive fields\n  * Mild, moderate or advanced disease on mean deviation according to Hodapp classification\n  * Healthy, mobile conjunctiva in the target quadrant (superior bulbar region)\n  * Best-corrected Snellen visual acuity of 20\u002F100 or better\n  * Visual field mean deviation no worse than -18.0 dB (without dense paracentral scotomas)\n* No anticipated need for other ocular surgeries (e.g., cataract) within 3 months of post-enrollment\n\nExclusion Criteria:\n\n* Prior glaucoma filtering surgery (trabeculectomy, shunt or valve) in the treatment quadrant\n* Angle-closure, neovascular, uveitic, or traumatic glaucoma.\n* Eyes with conjunctival scarring, prior conjunctival surgery or other pathologies in the treatment quadrant\n* Eyes with scleral thinning, staphyloma, or structural abnormalities in the treatment quadrant\n* Uncontrolled IOP \\> 35 mmHg at screening.\n* Active ocular infection or inflammation (e.g. blepharitis, conjunctivitis, keratitis, uveitis).\n* Active or recent (within 6 months) iris neovascularization in the treatment quadrant\n* Impaired episcleral venous drainage\n* Anterior chamber intraocular lens\n* Patients with uncontrolled bleeding disorders or those receiving anticoagulation therapy without appropriate perioperative management\n* Advanced glaucomatous optic neuropathy.\n* Fuchs endothelial dystrophy with clinical signs of endothelial decompensation.\n* Central corneal thickness (CCT) \\> 600 μm.\n* Pathological myopia.\n* Patients unable to comply with postoperative follow-up or treatment instructions\n* Women who are (i) pregnant, (ii) nursing, (iii) planning a pregnancy and (iv) of childbearing potential not using a reliable method of contraception as outlined below are excluded:\n\n  * Hormonal methods and the intrauterine device (IUD) must be in use at least 30 days prior to first study drug administration\n  * Barrier methods must be in use at least 14 days prior to study drug administration\n  * Your male partner vasectomy must be completed 3 months prior to first study drug administration or a sperm count of 0 should be confirmed.",{"count":7,"type":21},[53],"It is an interventional study for the treatment of Primary Open-Angle Glaucoma (POAG) using the Hexiris Microinvasive Scleral Trephine (MIST) system. This medical device includes a sclerectomy punch and injector assembly. It is a multicenter, open-label, non-randomized, single-arm study. Adults aged 40 years or more will be enrolled if the POAG is inadequately controlled by topical drug therapies. Only one eye per subject will be treated. The study will be performed on the first five patients in the operating room and the subsequent 20 patients will be treated under a slit-lamp in an aseptic environment (external patient clinic).Once treated with the MIST device, patients will return the next day, 1 week later and 1, 2, 3, 6, 9 and 12 months later. During these follow-up visits, the ophthalmologist will examine the eye and take measurements of the intraocular pressure.",[27],[261,262,263],"scleral trephine","surgical trabeculectomy","bleb-forming intervention","2026-01-14",{"date":266,"type":34},"2026-01-22",{"date":268,"type":34},"2026-01-15",{"date":270,"type":21},"2027-03-15",{"name":272,"class":41},"Hexiris Inc",5,{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":128},"100592272","omni-31-surgical-system-in-subjects-with-primary-open-angle-glaucoma-100592272","NCT06991270","OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma","A Pilot Study of the OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma","Inclusion Criteria:\n\n* Male or female subjects, 45 years or older\n* Visually significant age-related cataract and requiring phacoemulsification cataract surgery, OR, pseudophakic and a minimum of six months since cataract surgery.\n* Intraocular pressure (IOP) at the Screening visit not exceeding 33 mmHg and at least 21 mmHg for unmedicated eyes or 16 mmHg if medicated (1 to 4 ocular hypotensive medications - fixed combinations count as the number of components), with a stable medication regimen for ≥2 months.\n* Diagnosed with mild to moderate primary open angle glaucoma (POAG). Diagnosis must include evidence of glaucomatous optic nerve damage or visual field defect consistent with glaucomatous optic nerve damage\n\nExclusion Criteria:\n\n* Any of the following prior ocular procedures:\n\n  * Laser trabeculoplasty ≤180 days prior to baseline\n  * Durysta ≤12 months prior to baseline\n  * Any implanted glaucoma device\n  * Prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy\n  * Ciliary ablation including endoscopic cyclophotocoagulation (ECP), Cyclophotocoagulation or CPC (G probe), high intensity focused ultrasound (HIFU), ≤180 days prior to baseline\n  * Retinal laser procedure ≤3 months prior to baseline\n* Any form of glaucoma other than POAG.\n* Use of topical ocular steroids.\n* Clinically significant concurrent ocular pathology or systemic medical condition which, in the Investigator's judgment, would either place the subject at increased risk of complications, contraindicate surgery, place the subject at risk of significant vision loss during the study period (e.g., wet age-related macular degeneration (AMD), corneal edema, Fuch's dystrophy, active intraocular infection or inflammation within 30 days prior to Screening Visit, etc.), or interfere with compliance to elements of the study protocol (e.g., returning to Investigator's office for follow-up visits). Dry AMD and Non- proliferative diabetic retinopathy are not excluded.\n* History of penetrating keratoplasty or another corneal transplant; corneal abnormality that would prevent reliable IOP measurement, e.g. keratoconus or abnormally thick (≥ 620 µM) or thin (≤ 480 µM) cornea.\n* Retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.\n* BCVA of logMAR 0.4 (20\u002F50) or worse in the study eye not due to cataract.\n* BCVA of logMAR 0.6 (20\u002F80) or worse in the non-study eye not due to cataract.",{"count":7,"type":21},[53],"To gain early evidence of safety and assess the effectiveness of the intraocular pressure (IOP)-lowering effectiveness of the OMNI 3.0 Surgical System in primary open-angel glaucoma (POAG).",[27],"2026-01-12",{"date":264,"type":34},{"date":288,"type":21},"2026-02",{"date":290,"type":21},"2027-05",{"name":292,"class":41},"Sight Sciences, Inc.",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":301,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":128},"100459607","assessment-of-endothelial-glycocalyx-in-patients-with-primary-open-angle-glaucoma-100459607","NCT05264818","Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma","Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma: a Prospective Single-center Cross-sectional Case-control Study","GLAUCALYX","Inclusion Criteria:\n\n* Express consent to participate in the study\n* Only for case group: primary open angle glaucoma (defined as the presence of visual field damage attributed to glaucomatous optic neuropathy) in both eyes\n* Only for control group: Absence optic nerve pathology (including primary open angle glaucoma)\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Sleep apnea\n* Renal insufficiency\n* Parkinson's disease\n* Alzheimer's disease\n* Antiphospholipid syndrome\n* Cancer for which treatment ended less than 2 years ago\n* Stroke less than 1 year ago\n* Myocardial infarction less than 1 year ago",true,{"count":303,"type":21},100,"The glycocalyx is a fibrillary lining structure that covers the inner surface of blood vessels. Composed of glycoproteins and polysaccharides, it is an essential determinant of vascular endothelial physiology: it limits coagulation activation and adapts capillary perfusion. Studies have shown glycocalyx alteration in various vascular and autoimmune pathologies such as diabetes, high blood pressure, chronic renal failure, ischemic heart disease, stroke, dementia, septic shock, and several other inflammatory pathologies with a common basis in vascular insufficiency.\n\nGlaucoma is a progressive, chronic and asymptomatic optic neuropathy characterized by visual field damage and abnormalities of the optic nerve head. Two hypotheses have been proposed as a basis for this progressive damage:\n\n* the mechanical theory, which explains the papillary excavation by a compression of the optic nerve head under the effect of high intraocular pressure; and\n* the ischemic theory, explained by a circulatory insufficiency at the level of the blood capillaries of the retina and especially of the optic nerve head. This latter theory is related to several pathologies that have circulatory insufficiency as common underlying pathophysiology, and in which damage to the glycocalyx has been well studied.\n\nGlycocalyx damage has rarely been studied in glaucoma. Yang et al. showed that the glycocalyx, present in Schlem's canal, plays a major role in the transduction of shear stress and regulation of outflow resistance to the aqueous humor, which may constitute an interesting biomarker for glaucomatous pathologies.",[306,210],"Primary Open-angle Glaucoma",[308,309,310,306,210],"Glycocheck","Sublingual microvascularization","Glycocalyx","2025-12-02",{"date":313,"type":34},"2025-12-08",{"date":315,"type":34},"2022-05-06",{"date":317,"type":21},"2026-05",{"name":319,"class":320},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":301,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":330,"conditions":331,"keywords":333,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":128},"100074357","diagnostic-innovations-in-glaucoma-study-100074357","NCT00221897","Diagnostic Innovations in Glaucoma Study","DIGS","Inclusion:\n\n* Subjects are healthy controls with or without myopia, and patients with or without myopia with a diagnosis of glaucoma, glaucoma suspect and ocular hypertension\n* They will be considered if they are above 18 years old.\n* There is no upper age limit\n* Subject are not restricted by gender, race or ethnicity.\n\nExclusion:\n\n-Participants with other ocular or systemic conditions and treatment, which may affect visual function, are excluded.",{"count":329,"type":21},3000,"The overarching goal of our research study is to evaluate changes in visual function and optic nerve topography (the structure of the back of the eye) in patients with glaucoma (increased susceptibility to pressure inside the eye that can cause loss of vision) or those with an increased risk of developing the disease. The purpose of this study is to determine the best methods for detecting the presence or progression (worsening over time) of glaucoma in patients with and without myopia and its effects on daily and visual function and quality of life. With several sources of NIH and foundation funding over the last twenty years we have designed a robust research protocol to address the most challenging aspects of glaucoma management. The most recent focus of this research is 1) to improve our ability to detect open angle glaucoma in individuals with myopia and in individuals of European and African descent, 2) to determine whether monitoring of the retinal vasculature with new optical imaging instruments can improve glaucoma management and elucidate the pathophysiology of the disease, and 3) to differentiate between age-related changes and glaucomatous progression.\n\nThe grants supporting this project include 3 NIH funded studies, 1) the University of California, San Diego UCSD -based \"Diagnostic Innovations in Glaucoma Study\" (DIGS funded since 1995): 2) the \"African Descent and Glaucoma Evaluation Study\" (ADAGES funded since 2002), 3) the Brightfocus Foundation National Glaucoma Research Program and 4) the UCSD-based \"Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography Angiography\" (funded since 2018). The ADAGES is a multi-center study with data collection also conducted at 2 other academic sites, the University of Alabama at Birmingham, and Columbia University.\n\nEnrolled healthy participants, glaucoma suspects and glaucoma patients are generally asked to return for two or more visits a year for several years. We then analyze whether the glaucoma patients are progressing and what factors influence their glaucoma status compared to healthy subjects and individuals suspected of having glaucoma.",[27,332],"Myopia",[334,335,336,337,338],"Primary open angle glaucoma","Glaucoma\u002Fpathology","Glaucoma\u002Fphysiopathology","Nerve Fibers\u002Fpathology","Risk factors glaucoma","2025-10-23",{"date":341,"type":34},"2025-10-24",{"date":343,"type":4},"1995-04",{"date":345,"type":21},"2030-07",{"name":347,"class":127},"University of California, San Diego",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":301,"sex":17,"minAge":73,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":128},"100392898","glaucoma-visual-field-loss-and-their-association-with-life-space-in-older-adults-100392898","NCT04396002","Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults","Inclusion Criteria (Patients):\n\n* Participants that are enrolled in the Early Detection of Glaucoma Progression using a Novel Individualized Approach (IRB-300000301) or in the African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the Lamina Cribrosa in Progression (IRB-161115004).\n\nExclusion Criteria (Patients):\n\n* Not being enrolled in one of the following two NIH-funded studies: 1. African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progression (EY026574) or 2. Early detection of glaucoma progression using a novel individualized approach (EY025756)\n\nInclusion Criteria (Controls):\n\n* No diagnosis of eye disease\n\nExclusion Criteria (Controls):\n\n* Cognitive impairment that would preclude ability to take the tests","100 Years",{"count":303,"type":21},"Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy that can lead to gradual loss of vision in the peripheral field and central vision. Older adults with POAG have an increased risk for motor vehicle collisions and falls. Moreover, existing studies suggest that patients with POAG exhibit more postural sway while standing as measured by a balance platform and also tend to walk more slowly than those who are normally sighted and free of ocular disease. While these disturbances likely influence mobility, there has been little research directly assessing the impact of POAG on mobility. This study will assess the impact of POAG on life space (one aspect of mobility) and will determine whether difficulties with life space are associated with difficulties experienced under conditions of dim lighting.",[27],"2025-09-05",{"date":360,"type":34},"2025-09-12",{"date":362,"type":34},"2019-06-01",{"date":364,"type":21},"2026-05-30",{"name":366,"class":127},"University of Alabama at Birmingham",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":128},"100589004","a-study-of-the-helix-surgical-system-in-primary-open-angle-glaucoma-poag-and-cataract-helix-100589004","NCT06948773","A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)","A Pilot Study of the Helix Surgical System in Subjects With Primary Open-Angle Glaucoma (POAG) and Cataract.","HELIX","Inclusion Criteria:\n\n* Male or female subjects, 45 years or older\n* Visually significant age-related cataract.\n* Intraocular pressure (IOP) at the Screening visit not exceeding 33 mmHg and at least 21 mmHg for unmedicated eyes or 16 mmHg if medicated (1 to 4 ocular hypotensive medications - fixed combinations count as the number of components), with a stable medication regimen for ≥2 months.\n* Diagnosed with mild to moderate primary open angle glaucoma (POAG).\n\nExclusion Criteria:\n\n* Any of the following prior ocular procedures:\n\n  * Laser trabeculoplasty ≤180 days prior to baseline\n  * Durysta ≤12 months prior to baseline\n  * Any implanted glaucoma device\n  * Prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy\n  * Ciliary ablation including endoscopic cyclophotocoagulation (ECP), Cyclophotocoagulation or CPC (G probe), high intensity focused ultrasound (HIFU),\n\n    * 180 days prior to baseline\n  * Retinal laser procedure ≤3 months prior to baseline\n* Any form of glaucoma other than POAG\n* Use of topical ocular steroids.\n* Clinically significant concurrent ocular pathology or systemic medical condition which, in the Investigator's judgment, would either place the subject at increased risk of complications, contraindicate surgery, place the subject at risk of significant vision loss during the study period or interfere with compliance to elements of the study protocol\n* History of penetrating keratoplasty or another corneal transplant\n* Endothelial cell density \\\u003C 2200 cells\u002Fmm2 (age 45), \\\u003C 2000 cells\u002Fmm2 (age 46 to 55), \\\u003C 1800 cells\u002Fmm2 (age 56 to 65), \\\u003C 1600 cells\u002Fmm2 (age \\> 65).\n* Retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.\n* BCVA of logMAR 0.4 (20\u002F50) or worse in the study eye not due to cataract\n* BCVA of logMAR 0.6 (20\u002F80) or worse in the non-study eye not due to cataract.",{"count":7,"type":21},[53],"A study to assess the safety of the Helix Surgical System in cataract surgery and to gain early evidence of its effectiveness in lowering intraocular pressure (IOP) in subjects with mild to moderate primary open-angle glaucoma (POAG) and cataracts.",[27,379],"Cataract","2025-07-15",{"date":382,"type":34},"2025-07-16",{"date":384,"type":34},"2025-05-21",{"date":386,"type":21},"2026-09-30",{"name":292,"class":41},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":409,"locationsCount":128},"100598808","a-prospective-study-on-the-efficacy-of-direct-selective-laser-trabeculoplasty-dslt-in-achieving-20-intraocular-pressure-iop-reduction-without-medications-at-6-months-in-naive-untreated-glaucoma-patients-100598808","NCT07076303","A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients","Inclusion Criteria:\n\nAdults aged 18 years or older:\n\nParticipants must be adults, aged 18 years or older, to ensure they are capable of providing informed consent and to focus on adult-onset glaucoma. This age threshold allows the study to target a population where open-angle glaucoma typically manifests, avoiding potential variations in outcomes that might arise in younger populations with different types of ocular conditions.\n\nDiagnosis of naive, untreated open-angle glaucoma or similar conditions:\n\nThe study is restricted to individuals who have been newly diagnosed with primary open-angle glaucoma and have not yet received any form of treatment, either pharmacological or surgical. This ensures that the effects of DSLT (Direct Selective Laser Trabeculoplasty) are evaluated without the confounding influence of prior treatments.\n\nOther similar conditions may include ocular hypertension or other early-stage glaucomatous conditions where IOP reduction is indicated (ie: pigment dispersion syndrome\u002Fglaucoma and pseudoexfoliation). This broadens the inclusion slightly to capture patients with conditions that have a similar disease mechanism and treatment goal, without including those with more complex or mixed forms of glaucoma.\n\nExclusion Criteria:\n\nPrevious glaucoma surgeries\u002Finterventions:\n\nPatients who have undergone prior glaucoma-related surgeries (e.g., trabeculectomy, laser trabeculoplasty, or shunt procedures) or received other significant glaucoma interventions (such as long-term glaucoma medication use) are excluded. This criterion ensures the study evaluates the effect of DSLT in a treatment-naive population. Prior surgeries or interventions could bias the results by introducing variability in eye physiology, making it difficult to attribute outcomes solely to DSLT.\n\nSecondary glaucoma or other significant ocular conditions:\n\nPatients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases, are excluded. These conditions often have different pathophysiological mechanisms, which could lead to varied responses to DSLT.\n\nOther significant ocular conditions that could interfere with the study include advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function. Excluding these conditions ensures a clearer evaluation of DSLT's effects on open-angle glaucoma without interference from unrelated ocular abnormalities.\n\n3\\. Patients who are unable to fixate their head and\u002For eyes, such as patients suffering from uncontrolled nystagmus, tremors, or similar conditions.\n\n4\\. Patients with a pupil that cannot constrict to a diameter of 4 mm or less.\n\nIn summary, these criteria focus on a specific and controlled population of treatment-naive glaucoma patients to provide a clean evaluation of the effectiveness and safety of DSLT, while excluding individuals whose prior treatments or other conditions could skew the results.",{"count":184,"type":21},"Background\n\nGlaucoma is a progressive optic neuropathy characterized by elevated intraocular pressure (IOP), leading to irreversible vision loss. Current treatment strategies often involve medications, which can be challenging for patients due to adherence issues and side effects. Direct Selective Laser Trabeculoplasty (DSLT) represents a potential surgical alternative for managing IOP in patients with naive, untreated glaucoma. This study aims to evaluate the efficacy of DSLT in achieving significant IOP reduction without the need for postoperative medications.\n\nUnmet Medical Need:\n\nOverview of DSLT\n\nDirect Selective Laser Trabeculoplasty (DSLT) is an emerging technology in glaucoma management that combines laser techniques to reduce intraocular pressure (IOP). While it works off the auspices of a previous technology (SLT), the method of delivery is significantly different.\n\nCurrent Research Landscape\n\nMost existing studies focus on patients who have already received other forms of treatment or who have more advanced glaucoma. This creates an unmet need to evaluate how DSLT can be effectively integrated into the management of patients at the very beginning of their glaucoma journey. Understanding its efficacy in this population is crucial for establishing best practices and improving long-term outcomes.\n\nInterventional Glaucoma Management vs. Standard of Care\n\nStandard of care for newly diagnosed glaucoma typically involves medications, such as topical prostaglandin analogs, which can have side effects and may not be effective for all patients. In contrast, interventional glaucoma management-such as DSLT-offers a potentially more direct approach to lowering IOP without the need for ongoing medication. Investigating DSLT in this context could lead to a paradigm shift in how newly diagnosed patients are managed, reducing their reliance on medications and potentially improving adherence and quality of life.\n\nConclusion\n\nAddressing this research gap will not only help clarify the role of DSLT in early glaucoma management but could also enhance patient outcomes and guide future treatment protocols. Focusing on newly diagnosed patients is essential for determining the long-term benefits and risks associated with this innovative technology.",[27,210,397],"Primary Open Angle Glaucoma or Ocular Hypertension",[112,399,400,401,402],"primary open angle glaucoma","direct SLT","SLT","selective laser trabeculoplasty","2025-07-14",{"date":405,"type":34},"2025-07-22",{"date":407,"type":34},"2002-03-11",{"date":145,"type":21},{"name":410,"class":127},"Brian Shafer",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":204,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":22,"phases":419,"briefSummary":421,"conditions":422,"keywords":423,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":429,"leadSponsor":431,"locationsCount":128},"100596700","phase-4-rocklatan-adds-pressure-reduction-after-migs-minimally-invasive-glaucoma-surgery-100596700","NCT07048886","Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)","Inclusion Criteria:\n\n* Age 40 years and older\n* Subjects who have mild to moderate Open Angle Glaucoma (OAG)\n* Subjects who have undergone uncomplicated cataract surgery and Hydrus microstent implantation \\> 3 months prior to screening and within the last 2 years\n* Post-Hydrus subjects on 0-2 ocular hypotensive medication classes who can safely washout (if on ocular hypotensive medications)\n* Unmedicated or washed out IOP range between 16-26 mmHg\n\nExclusion Criteria:\n\n* History of intraocular surgery except for uneventful refractive surgery or uncomplicated cataract surgery and hydrus microstent implantation\n* Prior Selective Laser Trabeculoplasty (SLT) within 18 months of surgery\n* Secondary glaucoma excluding pseudoexfoliation and pigmentary dispersion syndrome\n* Severe Open Angle Glaucoma\n* Narrow angles, other angle abnormalities or angle closure glaucoma\n* Allergy or intolerance to Rocklatan\n* History of corneal edema, or corneal disease or dystrophy\n* Current or history of intra-ocular infection or inflammation\n* History of retinal diseases that could affect diagnostic testing\n* Anticipated use of intra-ocular or topical steroids not associated with the study protocol\n* Pregnant, breastfeeding or planning to become pregnant during the study\n* Any condition in the opinion in the investigator that would potentially confound the results of the study",{"count":418,"type":21},68,[420],"PHASE4","The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.",[27],[27,424],"Rocklatan","2025-06-30",{"date":427,"type":34},"2025-07-03",{"date":380,"type":21},{"date":430,"type":21},"2026-12-31",{"name":432,"class":127},"Center for Sight Las Vegas",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":128},"100472997","xen-glaucoma-gel-stent-versus-trabeculectomy-100472997","NCT05439161","XEN Glaucoma Gel Stent Versus Trabeculectomy","Multicentric Evaluation of Best Corrected Visual Acuity of the XEN Implant Versus Classic Trabeculectomy in Open Angle Glaucoma Subjects","Inclusion Criteria:\n\n1. Diagnosis of open angle glaucoma (Primary open angle glaucoma, Pseudoexfoliation glaucoma, Pigmentary dispersion glaucoma)\n2. Clinically eligible for both surgeries (Trabeculectomy and XEN) on the discretion of the surgeon (area of healthy, free and mobile conjunctiva in the superior nasal target quadrant)\n3. VA logMAR ≤ 1 (VA dec ≥ 0.1)\n4. Trabecular meshwork must be visible (with Shaffer angle grade \\> 1 in the target quadrant)\n5. Age 18 years or older\n6. Patient understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provides written informed consent\n\nExclusion Criteria:\n\n1. Clinical significant cataract\n2. Subject has had prior cataract surgery in study eye ≤ 1 months (count to operation)\n3. Subject has had prior (incisional) glaucoma surgery (XEN, trabeculectomy, viscocanalostomy, canaloplasty, shunts of any type, collagen implants, etc.). Prior iridotomy is acceptable.\n4. Phacic Angle Closure Glaucoma\n5. Subject has neovascular, uveitic or angle recession glaucoma or any glaucoma associated with vascular disorders\n6. Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis)\n7. Anterior chamber intraocular lens\n8. Vitreous present in the anterior chamber\n9. Presence of intraocular silicone oil\n10. History of corneal surgery, corneal opacities, or corneal disease\n11. Impaired episcleral venous drainage (e.g. Sturge-Weber or nanophthalmos)\n12. History of dermatologic keloid formation\n13. Active diabetic retinopathy, proliferative retinopathy, choroidal neovascularization, branch retinal vein occlusion, central retinal vein occlusion, or other ophthalmic disease or disorder that could confound study results\n14. Known or suspected allergy or sensitivity to drugs required for the surgical procedure or any of the device components (e.g., porcine products or glutaraldehyde),\n15. Pregnant or nursing women",{"count":441,"type":21},196,[53],"Multicentric evaluation of best corrected visual acuity of the XEN implant versus classic trabeculectomy in open angle glaucoma subjects",[27,110,445],"Pigmentary Dispersion Glaucoma","2025-05-28",{"date":448,"type":34},"2025-06-03",{"date":450,"type":34},"2023-12-20",{"date":386,"type":21},{"name":453,"class":127},"Prof. Dr. Herbert Reitsamer",{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":301,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":22,"phases":463,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":128},"100356509","retinal-photoreceptor-outer-segment-length-before-and-after-light-stimulation---a-pilot-study-100356509","NCT03921931","Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study","Assessment of Retinal Photoreceptor Outer Segment Length With Optical Coherence Tomography Before and After Light Stimulation - a Pilot Study","Inclusion Criteria:\n\n* men and women aged over 18 years\n* signed informed consent form\n* ametropia below 3 diopters\n* ability and willingness to follow instructions\n\nfor healthy volunteers:\n\n* normal ophthalmologic findings\n\nfor primary open angle glaucoma patients (POAG):\n\n* diagnosed POAG\n* MD \\\u003C= 10 dB\n\nfor age-related macular degeneration (AMD):\n\n* diagnosed dry AMD\n* diagnosed stage II or stage III AMD\n\nExclusion Criteria:\n\n* Presence of any abnormalities preventing reliable measurements\n* Ocular inflammation and ocular disease interfering with the study aims\n* Use of photosensitizing medication (phototoxic drugs, photoallergic drugs) in the 3 months preceding the study\n* Presence of any condition with the possibility of causing photosensitivity, including systemic lupus erythematosus SLE, Porphyria, Vitiligo, Xeroderma Pigmentosum and Albinism\n* Presence of any form of epilepsy\n* Ocular surgery in the 3 months preceding the study\n* Pregnancy, planned pregnancy or lactating\n* Any medical or surgical history, disorder or disease such as acute or chronic severe organic disease",{"count":462,"type":21},35,[53],"It has been shown that reactions of human retinal photoreceptors to a light stimulus can be measured with custom-made, research prototype optical coherence tomography (OCT) systems. This can be used as a biomarker for the function of the photoreceptors. Due to the high technical demands on the system, however, the technique is currently not available for clinical purposes. In this pilot study a protocol to measure changes in retinal photoreceptor layer thickness before and after light stimulation shall be developed based on a commercial OCT system and newly developed algorithms. Other variables, such as circadian processes shall be investigated as well. After measurements in healthy volunteers, the protocol is planned to be applied in patients with primary open angle glaucoma (POAG) and age-related macular degeneration (AMD) to test for feasibility of the method in these patient groups.",[466,306],"Macular Degeneration, Dry",[468,469,470,471,472,473],"light stimulation","retinal photoreceptors","light adaptation","functional optical coherence tomography","optophysiology","intrinsic optical signals","2025-05-13",{"date":476,"type":34},"2025-05-16",{"date":478,"type":34},"2018-11-26",{"date":480,"type":21},"2026-05-31",{"name":482,"class":127},"Medical University of Vienna",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":491,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":495,"conditions":496,"keywords":497,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":273},"100499664","multicenter-glaucoma-study-investigating-standalone-canaloplasty-100499664","NCT05786196","Multicenter Glaucoma Study Investigating Standalone Canaloplasty","Multicenter Glaucoma Study Investigating Standalone Canaloplasty, Randomized Controlled Trial: iTrack Advance (Nova Eye, Inc.) Compared to OMNI (Sight Sciences)","MAGIC","Inclusion Criteria:\n\n* Male or female subjects, 22 years or older at the time of surgery\n* Diagnosed with mild to moderate primary open angle glaucoma\n* Candidate for canaloplasty surgery: i.e., catheterization of Schlemm's canal and subsequent viscodilation of Schlemm's canal, without trabeculotomy\n* Intolerance to medical therapy OR need\u002Fwillingness to reduce medications\n* At the Screening Visit, IOP of ≤ 30 mmHg while on 1-4 ocular hypotensive medications\n* At the Baseline Visit, unmedicated IOP ≥ 21mmHg and ≤ 36 mmHg, and ≥ 3mmHg higher than medicated IOP\n* Shaffer grade of ≥ 3 in all four quadrants\n* Central corneal thickness ≥ 480µm and ≤ 620 µm\n* Able and willing to comply with the study procedures and attend all follow-up visits\n* Understands and signs the informed consent\n\nExclusion Criteria:\n\n* Any of the following prior treatments for glaucoma (study eye):\n\n  1. Laser trabeculoplasty\n\n     i. Selective Laser Trabeculoplasty (SLT) conducted within 6-months of the Screening Visit ii. Prior Argon Laser Trabeculoplasty\n  2. iStent or iStent Inject within 180 days of the Screening Visit\n  3. Endocyclophotocoagulation (ECP) or Micropulse laser\n  4. Trabeculectomy or other bleb forming procedure including Xen, Express, and glaucoma draining device\u002Fvalve\n  5. Prior canaloplasty (ab interno and ab externo)\n  6. Prior goniotomy, or trabeculotomy (ab externo and ab interno)\n  7. Hydrus microstent\n  8. Suprachoroidal stent (e.g., Cypass, iStent Supra, MINIject)\n  9. Concurrent IOP-lowering procedure other than use of the iTrack Advance canaloplasty device OR the OMNI Surgical System at the time of surgery (e.g., ECP, CPC, etc.)\n* Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma, pigmentary glaucoma or pseudoexfoliative glaucoma\n* Cataract surgery within 6 months of the Screening Visit in the study eye\n* History of fellow eye with cataract surgery within 30 days of Screening\n* Subjects at significant risk by a washout of ocular hypotensive medication, and\u002For subjects where the unmedicated IOP is expected to exceed the upper limit of 36 mmHg\n* Use of systemic medications (either current, within 30 calendar days of Screening exam, or anticipated) that may cause an increase in IOP, (e.g., systemic steroids including inhaled and oral steroids used on a regular basis)\n* Ocular and\u002For systemic diseases that could affect the corneal endothelium (such as corneal endothelial dystrophy, intraocular inflammation and infection, or congenital abnormalities)\n* History of penetrating keratoplasty or another corneal transplant\n* BCVA of 20\u002F200 or worse in the fellow eye not due to cataract\n* Previous treatment with OMNI or iTrack (Note: permitted if fellow eye only was treated)\n* BCVA of 20\u002F50 or worse in the study eye not due to posterior capsular opacification","22 Years",{"count":493,"type":21},86,[53],"A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrack™ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight Sciences) in patients with mild to moderate primary open-angle glaucoma.",[27],[498],"Canaloplasty","2025-04-15",{"date":501,"type":34},"2025-04-18",{"date":503,"type":34},"2023-05-09",{"date":505,"type":21},"2026-12",{"name":507,"class":41},"Nova Eye, Inc.",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":512,"acronym":513,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":17,"minAge":515,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":521,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":528},"100482596","cataract-surgery-in-conjunction-with-ab-interno-canaloplasty-compared-to-cataract-surgery-only-in-patients-with-mild-to-moderate-primary-open-angle-glaucoma-100482596","NCT05564091","Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma","CATALYST","Inclusion Criteria:\n\n* Mild to moderate, primary open angle glaucoma\n* Characteristics consistent with mild to moderate glaucoma\n* Use of 1 - 4 ocular hypotensive medications at the Screening exam and meets the IOP (intraocular pressure) criteria\n* Visually significant cataract\n\nExclusion Criteria:\n\nAny of the following prior treatments for glaucoma (study eye):\n\n* Laser Trabeculoplasty\n* Endocyclophotocoagulation (ECP) or Micropulse laser\n* iStent or iStent Inject\n* Hydrus Microstent\n* Trabeculectomy or other bleb forming procedure including Xen, Express, and glaucoma drainage device\u002Fvalve.\n* Prior canaloplasty (ab-interno and ab-externo)\n* Prior goniotomy, or trabeculotomy (ab-interno or ab-externo)\n* Suprachoroidal stent (e.g., Cypass, iStent Supra, XEN, MINIject)\n* Concurrent IOP-lowering procedure other than use of the iTrackTM Advance canaloplasty device at the time of surgery (e.g., ECP, CPC, etc.)\n* Previous treatment with iTrack (Note: permitted if fellow eye only was treated)\n* Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma","55 Years",{"count":517,"type":21},78,[53],"A prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.) to cataract surgery only in patients with mild to moderate, primary open angle glaucoma. Subjects will be followed for 24 months.",[27],[498],{"date":501,"type":34},{"date":524,"type":34},"2022-09-08",{"date":526,"type":21},"2027-07",{"name":507,"class":41},4,{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":204,"maxAge":74,"enrollmentInfo":536,"targetDuration":4,"studyType":22,"phases":538,"briefSummary":539,"conditions":540,"keywords":541,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":128},"100540200","safety-and-effectiveness-of-minimally-invasive-micro-sclerostomy-mims-to-reduce-intraocular-pressure-in-open-angle-glaucoma-which-is-not-controlled-despite-polypharmacy-100540200","NCT06313749","Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy","An Observer-Masked, Single-Arm, Multicenter Study to Evaluate the Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy","Inclusion Criteria:\n\n1. Male or female, ≥ 40 years to ≤ 85 years old\n2. Inadequately controlled primary open angle glaucoma with screening mean diurnal IOP of ≥ 21 mmHg and ≤ 40 mmHg despite polypharmacy\n3. Primary open angle glaucoma diagnosis based on:\n\n   1. Visual field mean deviation of -3dB or worse and\n   2. Glaucomatous optic nerve damage as evidenced by optic disc or retinal nerve fiber layer structural abnormalities documented on slit lamp stereo biomicroscopy or in stereo disc photos\n4. Presence of healthy, free, and mobile conjunctiva in the target quadrant\n5. Prior ab interno conjunctival-sparing glaucoma procedures were conducted more than 6 months prior to enrollment (e.g., iStent, Trabectome, gonioscopy-assisted transluminal trabeculectomy \\[GATT\\])\n6. Subject is able and willing to attend all scheduled follow-up exams\n7. Subject understands and signs the informed consent",{"count":537,"type":21},129,[53],"The goal of this clinical trial is to show non-inferiority of the MIMS® device\u002Fprocedure with Mitomycin-C, in terms of its surgical success rate, compared to trabeculectomy with Mitomycin-C in subjects diagnosed with primary open angle glaucoma, whose intraocular pressure is not controlled despite polypharmacy.\n\nEligible screened participants will undergo the MIMS® procedure and will be followed for a period of 12 months in this single-arm study. Investigators will compare the results of this study to the surgical success rate of traditional trabeculectomy with Mitomycin-C.",[27,107],[107,542,543,544,545,546,547],"Polypharmacy","Intraocular Pressure","MIMS","Minimally Invasive Glaucoma Surgery","MIGS","MTMT","2024-08-06",{"date":550,"type":34},"2024-08-07",{"date":552,"type":34},"2024-06-01",{"date":554,"type":21},"2025-12",{"name":556,"class":41},"Sanoculis Ltd",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":491,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":565,"briefSummary":566,"conditions":567,"keywords":568,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":578},"100533225","phase-2-a-study-of-amdx-2011p-in-participants-with-primary-open-angle-glaucoma-100533225","NCT06223048","A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma","A Phase 2, Randomized, Open Label Study of AMDX-2011P as a Retinal Tracer in Participants With Primary Open Angle Glaucoma","Inclusion Criteria:\n\n1. Diagnosis of primary open angle glaucoma in both eyes\n2. Able to fixate\n3. Glaucomatous optic nerve damage in both eyes, as determined by an investigator as part of an eye exam\n\nExclusion Criteria:\n\n1. Participants unable to read or write\n2. Ocular media is not sufficiently clear to obtain acceptable quality images\n3. Participants with presence of any ocular pathology other than glaucoma in the study eye (cataracts are acceptable)",{"count":206,"type":21},[104],"The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).",[27],[81],"2024-07-29",{"date":571,"type":34},"2024-07-30",{"date":573,"type":34},"2023-12-07",{"date":575,"type":21},"2025-02",{"name":577,"class":41},"Amydis Inc.",3,{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":588,"conditions":589,"keywords":590,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":4},"100556539","the-objective-is-to-evaluate-the-anterior-chamber-angle-after-bang-procedure-the-study-will-recruit-12-patients-who-will-undergo-planned-goniectomy-for-uncontrolled-poag-anterior-segment-oct-scan-will-be-used-to-evaluate-the-anterior-chamber-postoperatively-100556539","NCT06526416","The Objective is to Evaluate the Anterior Chamber Angle After BANG Procedure, the Study Will Recruit 12 Patients Who Will Undergo Planned Goniectomy for Uncontrolled POAG, Anterior Segment OCT Scan Will Be Used to Evaluate the Anterior Chamber Postoperatively.","Anterior Chamber Angle Changes After Bent Angle Needle Goniectomy Procedure, Anterior Segment OCT Study","Inclusion Criteria:\n\n1. Patients who are being treated for primary open angle glaucoma using eye drops.\n2. Patients with uncontrolled intraocular pressure \\>21 mm Hg\n3. All recruited patients should have open anterior chamber angles demonstrated on gonioscopy examination.\n4. Patients giving consent for operation and follow up\n\nExclusion Criteria:\n\n* 1- Pseudophakic patients 2- Advanced glaucoma patients. 3- Patients who are to have trabeculectomy or laser trabeculoplasty. 4- Patients with secondary glaucoma. 5- Patients who are unable to give consent for surgery or follow up. 6- Patients with previous trauma to the eye",{"count":587,"type":21},12,"Evaluation of anterior segment using anterior segment optical coherence tomography in patients undergoing planned bent angle needle goniectomy procedure for uncontrolled open angle glaucoma.",[27,210],[591,592,334],"Bent angle needle goniectomy","anterior segment optical coherence tomography","2024-07-26",{"date":569,"type":34},{"date":596,"type":21},"2024-11-01",{"date":598,"type":21},"2025-01-01",{"name":600,"class":127},"Benha University",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":158,"enrollmentInfo":608,"targetDuration":4,"studyType":22,"phases":610,"briefSummary":611,"conditions":612,"keywords":613,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":622,"locationsCount":128},"100551857","crisprcas9-instantaneous-gene-editing-therapy-to-intraocular-hypertensive-poag-with-myoc-mutation-100551857","NCT06465537","CRISPR\u002FCas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation","A Clinical Study on CRISPR\u002FCas9 Instantaneous Gene Editing Therapy to Primary Open-angle Glaucoma With Elevated Intraocular Pressure and MYOC Gene Mutation","Inclusion Criteria:\n\n1. Signed ICF;\n2. Aged 18 to 65 years old;\n3. Primary open Angle glaucoma (POAG) with elevated intraocular pressure (IOP) was diagnosed with ≥1 year medical history record ;\n4. Good function level of organs;\n5. Good compliance and willing to comply with the visit schedule, laboratory tests and other specified test etc. per protocol;\n6. Agreeing to accept a long-term safety follow-up after 1 year of study.\n\nSpecial Inclusion Criteria for Group 1:\n\n* Target intervenning eye is no visual acuity;\n* The intraocular pressure (IOP) was ≤35 mmHg and \\> 21 mmHg after receiving a combination therapy of 2 or more drugs lowering IOP.\n\nSpecial Inclusion Criteria for Group 2:\n\n* MYOC gene mutation was detected in peripheral blood nucleated cells ;\n* The intraocular pressure (IOP) was ≤30 mmHg and \\> 21 mmHg after receiving a combination therapy of 2 or more drugs lowering IOP;\n* Both eyes have a Shaffer Angle mirror rating greater than 3.\n\nExclusion Criteria:\n\n1. Secondary glaucoma;\n2. Any active or recurrent intraocular infection or inflammation, including but not limited to uveitis;\n3. The target intervenning eye has severe xerophthalmia or clinically significant active corneal disease;\n4. Any condition no accepting the measure of IOP;\n5. Any positive of human immunodeficiency virus type 1\u002F2 (HIV-1\u002FHIV-2) antibody, treponema pallidum (TP) specific antibody, human T-lymphotropic virus type 1 or 2 (HTLV-1\u002FHTLV-2) antibody, or vesicular stomatitis virus G (VSV-G) antibody;\n6. Any of hepatitis B virus (HBV) HbsAg or HBV-DNA, hepatitis C virus (HCV) HCAb, or epstein-barr virus (EBV), or cytomegalovirus (CMV) nucleic acid test is positive;\n7. Severe active bacterial, viral, fungal, malaria or parasitic systemic infection;\n8. Any past or present malignancy, myeloproliferative or immunodeficient disease;\n9. History of major organ diseases or abnormalities in laboratory tests, including:\n\n   1. Liver cirrhosis, liver fibrosis or active hepatitis, and\u002For abnormal liver function tests (serum total bilirubin (TBIL) ≥1.5 x upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥2.5×ULN; Alkaline phosphatase ≥2.5 × ULN);\n   2. Cardiovascular and cerebrovascular diseases, including uncontrolled hypertension, myocardial infarction, myocarditis, arrhythmia, stroke, etc.;\n   3. Kidney disease, or creatinine ≥ 1.5ULN and creatinine clearance \\\u003C 30% normal level (using the Cockcroft-Gault equation);\n   4. Endocrine disorders, such as insulin-dependent diabetes mellitus, hyperthyroidism or hypothyroidism;\n   5. Severe pulmonary hypertension, chronic obstructive pulmonary disease, interstitial pneumonia;\n10. Any severe psychiatric disorders;\n11. Participating in another clinical study of a drug or device, or administrated the investigational drug within 42 days prior to the screening visit;\n12. Pregnant or lactating women;\n13. Refusing to accept any contraception measures;\n14. Allergic to clinical investigational drugs or their excipients;\n15. Other conditions assessed by the investigator as unsuitable for participation in this study.\n\nSpecial Exclusion Criteria for Group 2:\n\n* Retinal diseases: complicated with unexplained quadrant blindness, neovascularization age-related macular degeneration, retinal branch vein obstruction, central retinal vein obstruction, cystoid macular edema, macular hiatal hole and central serous retinopathy;\n* A history of anterior chamber angle stenosis, congenital glaucoma, or angle closure, clinically significant anterior peripheral adhesion, or extensive cicatricial adhesion caused by surgery\u002Flaser therapy in the anterior chamber angle;\n* The central corneal thickness is less than 480 μm or more than 620 μm.",{"count":609,"type":21},9,[53],"This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR\u002FCas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma (POAG) with elevated intraocular pressure and MYOC gene mutation. The main objectives to evaluate the safety and tolerability BD113vLVP) in POAG patients with intraocular hypertension and MYOC mutation, and secondary objectives is to explore the preliminary efficacy and the metabolism characteristics of BD113vLVP in participants.",[27],[399,81,614,615],"elevated intraocular pressure","MYOC gene mutation","2024-06-19",{"date":618,"type":34},"2024-06-24",{"date":620,"type":34},"2024-06-10",{"date":554,"type":21},{"name":623,"class":41},"Shanghai BDgene Co., Ltd."]